Circulating Tumor Cell Market Research Report- Forecast to 2027

Circulating Tumor Cell (CTC) Market Share, Growth and Trends Analysis By Application (Research, Drug Development), Technology (CTC Enrichment, CTC Detection), End-User (Hospital & Clinics, Research & Academic Institutes, Diagnostic Centers) - Forecast Till 2027

ID: MRFR/Pharma/0854-CR | August 2018 | Region: Global | 110 pages

Circulating Tumor Cell (CTC) Market

Circulating Tumor Cell (CTC) Market is expected to grow at a CAGR of 11.8% during the forecast period.

Segmentation

By Application Research Drug Development
By Technology CTC Enrichment CTC Detection
By End-User Hospital & Clinics Research & Academic Institutes Diagnostic Centers

Key Players

  • STEMCELL Technologies Inc.
  • QIAGEN
  • Sysmex Corporation
  • Bio-Techne Corporation
  • Menarini Silicon Biosystems
  • AVIVA Biosciences
  • ScreenCell
  • Fluxion Biosciences Inc.
  • Creativ MicroTech
  • Biolidics Limited

Drivers

  • Demand for minimally invasive treatment is rising rapidly
  • Rising rate of cancer
Speak to Analyst Request a Free Sample

Circulating Tumor Cell Market Overview 


The circulating tumor cell market size is expected to grow at a CAGR of 12.60% by the end of 2027. The cancer rate is increasing every year. Due to this, the range of cancer therapies is growing rapidly in many regions. More than 9.5 million men and 8.5 million women cancer cases are recorded around the world. The most common cancers are lung and breast affecting 18.5 million of the population. Most of the population in North America, Asia Pacific and Europe suffer from these diseases. Due to this the global cancer burden is tremendous. The rising rate of cancer is the demand driving factor for the circulating tumor cell market. 


Further, the circulating tumor cells circulate the body. They circulate through the blood circulatory system and lymphatic system. A circulating tumor cell is an effective tool for cancer diagnosis. Its non-invasive procedures and advantage are gaining more popularity in the market. Due to the prevalence of cancer extensive research is going on to find better treatment. The circulating tumor cell treatment proves to be beneficial for cancer patients. The massive research programs to prevent cancer will lead to the growth of the circulating tumor cell market. Also, all these factors will contribute to the high market value during the forecast period. 


Covid analysis 


The spread of the covid 19 viruses is taking a massive dig on global markets. The pharmaceutical companies and biotech sector is facing plenty of challenges. Due to the outbreak of covid 19, the development of vaccines is happening at an exponential pace. Most of the pharmaceutical companies are vaccine candidates. The research and development investments for the drug development market are immense. 


The vaccine development and supply chain is surging. Especially, hydroxychloroquine is witnessing exceptional demand during this period.


 These changes can bring a positive impact on the circulating tumor cell market. The growth of pharmaceutical and biotech companies will lead to high demand for circulating tumor cell market. The circulating tumor cell market will receive huge investments to carry out the operations. Also, the increased RD investment will lead to a new product launch. In the forecast period, the market expansion possibilities are higher for circulating tumor cells. 


Market dynamics 



  • Crucial market drivers 


The demand for minimally invasive treatment is rising rapidly. Most cancer patients prefer these non-invasive treatments. Due to this, the investments for minimally invasive treatments are increasing in the upcoming years. The invasive treatments come with plenty of side effects. Also, the pain and slow recovery are some of the limitations. However, with non-invasive procedures the trauma and side effects are limited. Further, the recovery from cancer is better. The awareness to adopt minimally invasive treatment is growing. Before choosing complex surgeries such as chemotherapy, radiotherapy and surgeries many patients prefer less invasive treatments.


 It leads to more adoption rate of non-invasive truants. These factors positively impact the circulating tumor cells prognostic technologies market. Moreover, the prevalence of cancer is another driver for the circulating tumor cell market. As per the national cancer institute, more death rates are recorded due to cancer. Almost 50000 new cancer cases are recorded every year. Colon cancer is the most prevalent cancer in many regions. Due to genetic disorders, high consumption of alcohol and lifestyle changes cancer cells attack the body. The prevalence of cancer calls for effective treatments. Due to this, the demand for the circulating tumor cell market is surging. 



  • The market growth opportunities


The vast application of circulating tumor cells will provide exceptional growth opportunities. The circulating tumor cells are mostly used for the prediagnosis of cancer. More focus on prediagnosis, pre-treatment and pre-clinical procedures will create more development opportunities.  The pretreatment application for cancer is very less. On the other hand, the main treatments such as chemotherapy and radiotherapy are more. The pretreatments for cancer lead to quick and better recovery. Directly going for complex surgeries can lead to many side effects. More awareness about preclinical treatments will create circulating tumor cell market growth opportunities.


The key players of the circulating tumor cell market are increasing production that will grow hemangioblastoma market size. It is one of the effective classes used for pre-treatment. Also, the pre-treatment such the enrichment and isolation products are having immense demand. The more production and focus of the market towards pre-treatment will bring a positive market growth rate. 



  • The market restraint 


The high cost of diagnosis is a significant restraint of the circulating tumor cell market. Circulating tumor cell treatment may be expensive for most of the population. Due to its wider benefits and better treatment the cost is high.


The materials and drugs used in the treatment are expensive. It is a restraining factor of the market that can decline the demand. Few technical difficulties in the market disturb the circulating tumor cells treatments. Both these factors can impact the overall growth of the circulating tumor cell market in the forecast period. 



  • The market challenges 


There is still a lack of awareness about circulating tumor cell products. Most cancer patients choose chemotherapy and radiotherapy. The awareness about these mainstream cancer treatments is high in many regions. However, the awareness about pretreatments such as circulating tumor cells is less.


Lack of awareness can hamper the overall expansion of the circulating tumor cell market. Also, the unwillingness of the patients to adopt circulating tumor cells is another serious challenge. Customer’s inclination to choose a medical treatment increases demand. However, the unwillingness of the patients can slow down the demand for the circulating tumor cell market. Also, it can lessen the growth opportunities for the market. 



  • Cumulative growth analysis 


The growth rate of the market is stable in the forecast period. There are plenty of factors during the demand for the circulating tumor cell market. The customer inclination towards minimally invasive treatment is driving demand. Further, the awareness about circulating tumor cells is escalating in the forecast period.


These factors constantly stir the demand. Moreover, the prediagnosis of circulating tumor cells is creating promising opportunities for the circulating tumor cell market. There is a lack of awareness about prediagnosis treatments in the market. It is a restraining factor that affects the overall market growth. Circulating the tumor cell market is expensive it leads to less demand effect on the market. 



  • Value chain analysis 


North America is leading the circulating tumor cell detection market in the forecast period. It will record the highest revenue rates than other regions. There are successful key players in the market. Innovations and investments are high for the market in the forecast period. The key players of the circulating tumor cell market are creating new strategies to develop the market. 


There are possibilities for product variation and new product launches. Further, the key payers are introducing cost-effective versions of the circulating tumor cells. All these will lead to plenty of developments in the circulating tumour cell market. 


Segment overview 


By technology 



  • Negative enrichment 

  • CTC enrichment 

  • Positive enrichment 


By detection methods 



  • CTC Detection Methods

  • Immunocytochemical Technology

  • Molecular (RNA)-based Technology


By application 



  • Cellular communication 

  • Multiple chromosome abnormalities

  • Protein expression 

  • RNA profiling 


By end-users 



  • Diagnostics centres 

  • Hospitals and clinics

  • Research and institutions


By geography 



  • North America 

  • Asia pacific 

  • Europe 


Competitive landscape 


The competition in the circulating tumor cell market is increasing rapidly. Market expansion, acquisitions and partnership are a crucial part of the competitive landscape. 


The research segment of the market will witness maximum demand. Also, the key players are creating more awareness for the market in the forecast period. Partnership with top institutes will create more awareness of the circulating tumor cell market. 


Regional analysis 


The circulating tumor cell market is fragmented into Asia Pacific, North America and Europe. North America will lead the market with the highest demand. Also, the shares for the market will increase in the forecast period. There are plenty of developments in the market. The generation of advanced tumour cells is happening in North America. It will widen the end-users.


Also, it is undertaking plenty of companies to expand the market. Furthermore, the Asia Pacific region will witness high market expansion. There are high possibilities of cancer in this region. Every year the new type of cancer diseases are rising. Technological advancement is the key factor driving the demand in this region. Infrastructural developments will bring plenty of developments to the market. Also, many unmet diagnostics needs will provide exceptional growth opportunities in this region. The need for early detection and prevention will drive demand in North America. 


The key players of the circulating tumor cell market are 



  • STEMCELL Technologies, Inc. 

  • QIAGEN

  • Sysmex Corporation

  • Bio-Techne Corporation

  • Menarini Silicon Biosystems

  • AVIVA Biosciences

  • ScreenCell

  • Fluxion Biosciences, Inc.

  • Creativ MicroTech,

  • Biolidics Limited

  • IVDiagnostics

  • Inc Ikonisys Inc.

  • Canopus Bioscience Ltd.


Recent developments 



  1. The bicep is improving the diagnosis of cancer treatment. It received the patent to carry out molecular analysis on cancer patients. 



  1. The key players are focusing more on colorectal cancer and its treatment. 


Report overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   12.60% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Application, Technology, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Ikonisys Inc., Greiner Bio-One International GmbH, Thermo Fisher Scientific, SRI International, STEMCELL Technologies, Miltenyi Biotec, Menarini Silicon Biosystems, QIAGEN Hannover (QIAGEN), F. Hoffmann-La Roche Ltd, NanoString Technologies, Inc, Fluxion Biosciences, Inc., GE Healthcare, ApoCell, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), Epic Lifesciences, Celltraffix Inc.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Clinical, research and drug development


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Circulating Tumor Cell Market is expected to touch a valuation of USD 28,300 million by 2023.

Circulating Tumor Cell Market stood at USD 9,393.1 million in 2017.

Circulating Tumor Cell Market can expand at a CAGR of 20.32% from 2018 to 2023.

Hospitals & clinics are predicted to be the biggest end-use segment of the Global Circulating Tumor Cell Market.

Americas can dominate the Global Circulating Tumor Cell Market.

ApoCell, F. Hoffmann-La Roche Ltd, Celltraffix Inc., QIAGEN Hannover (QIAGEN), STEMCELL Technologies, Thermo Fisher Scientific, Greiner Bio-One International GmbH, SRI International, GE Healthcare, Ikonisys Inc., NanoString Technologies, Inc, Fluxion Biosciences, Inc., Miltenyi Biotec, Menarini Silicon Biosystems, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), and Epic Lifesciences are the major players of the Global Circulating Tumor Cell Market.

Circulating Tumor Cells Market: Competitive Landscape


The circulating tumor cells market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.


The growth of the circulating tumor cell market players is dependent on market conditions, government support, and industry development. Thus, major players should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional players with small market shares also have a presence. International players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been estimated that improvement of the global economic scenario combined with efforts to enhance the infrastructure in emerging nations, is fueling the circulating tumor cell market growth, thereby making it an ideal time for new products and increase the global circulating tumor cell market share.


Players with better technical and financial resources can develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.



  1. Hoffmann-La Roche Ltd has a vast product portfolio in the circulating tumor cells industry. The company also has a wide geographic presence as it operates in various countries across the world. It has a significant presence in North America, Europe, and the Middle East and Africa, with commercial, manufacturing, and research facilities in more than one dozen countries.